Rejuve Biotech

Rejuve has established a separate branch and partner organization, Rejuve Biotech, to focus solely on therapeutics discovery and development in order to facilitate the discovery of new longevity therapeutics. Rejuve Biotech (RJB) is a health-span technology company that finds, develops, and tests new treatments and diagnostics using data and analysis from Rejuve Network. Rejuve Biotech will work closely with Rejuve Network to analyze the data that people and clinics send in using Rejuve's own AI framework, which is delivered via the blockchain-based decentralized network SingularityNET.

Rejuve Network takes on the responsibility and commits to its members that it will set a roadmap for progressive decentralization, will coordinate and oversee technology and other community services (including those outsourced to third parties), manage and develop all community communications and voting events, and coordinate Network-related proceeds and their usage, including issuing and managing the Rejuve (RJV) token.

Formally speaking Rejuve Biotech has the responsibility to:

i) Hold, manage and license out biodata on behalf of Rejuve Network ii) Administer sub-licenses on biodata contributed for research iii) Execute Statements of Work (SOW) handed down by the Network if and when needed.

When Rejuve Biotech's R&D based on Network biodata yields commercializable results, such as the monetization of research in terms of clinical trials and drug development economics, a portion of the revenue will be returned to Rejuve Network and used to provide benefits to members. Members of the Rejuve Network will be able to use this contribution to promote the network's objectives and provide incentives in a way that is appropriate to the community at large, and in particular to those token holders who have been the most active in terms of contributions.

By agreement between these two entities, Rejuve Network members are granted access to any treatments for extending their healthy lifespans derived from analyzing this data.